Bill Hoon Chang, M.D., Ph.D.
- Professor of Pediatrics, Division of Hematology and Oncology, School of Medicine
- Marsha and Richard Wright, Sr. Family Professor in Pediatric Oncology
Biography
Dr. Bill Chang cares for children, adolescents and young adults with cancer. He has special expertise in blood cancers. His research focuses on novel targets for therapy in blood cancers, including leukemia. He also teaches OHSU residents and fellows and mentors students and post-doctoral fellows within his research lab.
Dr. Chang is the director of the Leukemia and Lymphoma Program within OHSU's Division of Pediatric Hematology and Medical Oncology. He is also a member of OHSU's Pediatric Bone Marrow Transplant and Cellular Therapy Program.
When he's not working, Dr. Chang enjoys spending time with family and friends. He enjoys the outdoors, including mountain biking, alpine and backcountry skiing and hiking. He also enjoys "Airstreaming" – traveling by Airstream trailer.
Education and training
-
Degrees
- B.S., 1991, University of Washington
- Ph.D., 2000, Oregon Health & Science University
- M.D., 2000, Oregon Health & Science University
-
Residency
- Pediatrics, Oregon Health & Science University, 2003
-
Fellowship
- Fellowship in Pediatric Hematology/Oncology, Oregon Health & Science University, 2006
-
Certifications
- American Board of Pediatrics, 2003
- American Board of Pediatrics, Pediatric Hematology and Oncology 2006
Memberships and associations:
- American Academy of Pediatrics
- American Association for Cancer Research
- Children’s Oncology Group
- American Society for Blood and Marrow Transplantation
- American Society of Clinical Oncology
- American Society of Hematology
- American Society of Pediatric Hematology and Oncology
Areas of interest
- Novel targeted therapies
- Immunotherapies and Cellular Therapies
- Hematopoietic Stem Cell Transplantation
Publications
Elsevier pure profilePublications
Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML)
CancersThe genomic basis of childhood T-lineage acute lymphoblastic leukaemia
NatureClinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia Therapy
Blood cancer discoveryPatient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases
Clinical Cancer ResearchPatients with Down syndrome can be included in early phase clinical trials- a report from the T2016-003 Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) study
LeukemiaAssociating drug sensitivity with differentiation status identifies effective combinations for acute myeloid leukemia
Blood AdvancesDecitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML
American Journal of HematologyFetal Hepatomegaly
NeoReviewsIntegrative analysis of drug response and clinical outcome in acute myeloid leukemia
Cancer CellA phase 1 study of entinostat in children and adolescents with recurrent or refractory solid tumors, including CNS tumors
Pediatric Blood and CancerConcomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL
BloodDecitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia
Clinical Cancer ResearchSimultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia
LeukemiaExtracellular vesicles impose quiescence on residual hematopoietic stem cells in the leukemic niche
EMBO ReportsReplication timing alterations in leukemia affect clinically relevant chromosome domains
Blood AdvancesThe TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells
Cancer discoveryDasatinib plus intensive chemotherapy in children, adolescents, and young adults with philadelphia chromosome–positive acute lymphoblastic leukemia
Journal of Clinical OncologyFunctional genomic landscape of acute myeloid leukaemia
NatureMaintenance and pharmacologic targeting of ROR1 protein levels via UHRF1 in t(1;19) pre-B-ALL
OncogeneOutcome of children with multiply relapsed B-cell acute lymphoblastic leukemia
LeukemiaSynthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia
Science signalingClinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes
Journal of Clinical InvestigationEx vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia
BloodInvestigating the biology of relapsed acute leukemia
Pediatric Hematology and Oncology